Moderna Free Cash Flow Per Share vs Ev To Sales Analysis

MRNA Stock

USD 43.06 0.33 0.76%

Moderna financial indicator trend analysis is infinitely more than just investigating Moderna recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moderna is a good investment. Please check the relationship between Moderna Free Cash Flow Per Share and its Ev To Sales accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Free Cash Flow Per Share vs Ev To Sales

Free Cash Flow Per Share vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moderna Free Cash Flow Per Share account and Ev To Sales. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Moderna's Free Cash Flow Per Share and Ev To Sales is -0.1. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Moderna, assuming nothing else is changed. The correlation between historical values of Moderna's Free Cash Flow Per Share and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Moderna are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Free Cash Flow Per Share i.e., Moderna's Free Cash Flow Per Share and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.1

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Moderna's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.2 B, whereas Issuance Of Capital Stock is forecasted to decline to about 43.7 M.

	2021	2022	2023	2024 (projected)
Interest Income	18M	200M	405M	425.3M
Net Interest Income	18M	200M	363M	381.2M

Interest Income Net Interest Income

Moderna fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Other Current Assets	Total Liab	Deferred Long Term Liab	Total Current Assets	Intangible Assets	Common Stock	Other Current Liab	Common Stock Shares Outstanding	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments
Total Assets		0.86	0.99	0.91	0.93	0.93	0.92	0.87	0.84	0.78	0.91	-0.47	0.95	0.74	-0.98	0.61	0.7	0.95	0.89	0.64	-0.84	0.95	0.78	0.8	0.66	0.97
Total Current Liabilities	0.86		0.77	0.65	0.65	0.64	0.61	0.99	1.0	0.6	0.99	-0.14	0.95	0.63	-0.78	0.7	0.66	0.69	0.59	0.94	-0.99	0.79	0.42	0.92	0.55	0.92
Total Stockholder Equity	0.99	0.77		0.93	0.96	0.98	0.96	0.79	0.73	0.8	0.83	-0.54	0.9	0.73	-0.98	0.54	0.66	0.98	0.94	0.51	-0.74	0.96	0.86	0.71	0.65	0.94
Other Liab	0.91	0.65	0.93		0.95	0.91	0.96	0.69	0.62	0.67	0.72	-0.69	0.8	0.7	-0.92	0.47	0.76	0.96	0.95	0.38	-0.62	0.83	0.79	0.62	0.71	0.83
Net Tangible Assets	0.93	0.65	0.96	0.95		0.96	0.99	0.69	0.62	0.71	0.71	-0.73	0.8	0.75	-0.96	0.51	0.6	1.0	1.0	0.37	-0.62	0.87	0.85	0.62	0.67	0.86
Retained Earnings	0.93	0.64	0.98	0.91	0.96		0.98	0.66	0.6	0.75	0.71	-0.6	0.81	0.62	-0.97	0.41	0.55	0.97	0.95	0.34	-0.61	0.93	0.92	0.6	0.55	0.86
Accounts Payable	0.92	0.61	0.96	0.96	0.99	0.98		0.65	0.58	0.7	0.68	-0.73	0.78	0.7	-0.95	0.46	0.59	0.99	0.99	0.31	-0.57	0.87	0.88	0.58	0.65	0.84
Cash	0.87	0.99	0.79	0.69	0.69	0.66	0.65		0.99	0.59	0.99	-0.19	0.96	0.67	-0.81	0.65	0.65	0.72	0.63	0.91	-0.99	0.8	0.42	0.95	0.6	0.93
Net Receivables	0.84	1.0	0.73	0.62	0.62	0.6	0.58	0.99		0.55	0.98	-0.14	0.92	0.61	-0.76	0.67	0.63	0.66	0.56	0.95	-0.99	0.74	0.36	0.94	0.52	0.89
Other Current Assets	0.78	0.6	0.8	0.67	0.71	0.75	0.7	0.59	0.55		0.66	-0.22	0.75	0.72	-0.74	0.47	0.66	0.74	0.69	0.39	-0.56	0.82	0.7	0.48	0.64	0.76
Total Liab	0.91	0.99	0.83	0.72	0.71	0.71	0.68	0.99	0.98	0.66		-0.18	0.98	0.66	-0.83	0.7	0.7	0.75	0.66	0.9	-0.98	0.85	0.5	0.91	0.6	0.95
Deferred Long Term Liab	-0.47	-0.14	-0.54	-0.69	-0.73	-0.6	-0.73	-0.19	-0.14	-0.22	-0.18		-0.24	-0.5	0.55	-0.21	-0.29	-0.69	-0.77	0.09	0.12	-0.3	-0.52	-0.17	-0.41	-0.32
Total Current Assets	0.95	0.95	0.9	0.8	0.8	0.81	0.78	0.96	0.92	0.75	0.98	-0.24		0.71	-0.9	0.67	0.71	0.83	0.75	0.79	-0.92	0.93	0.64	0.87	0.67	0.99
Intangible Assets	0.74	0.63	0.73	0.7	0.75	0.62	0.7	0.67	0.61	0.72	0.66	-0.5	0.71		-0.68	0.63	0.59	0.75	0.74	0.48	-0.61	0.62	0.51	0.51	0.84	0.72
Common Stock	-0.98	-0.78	-0.98	-0.92	-0.96	-0.97	-0.95	-0.81	-0.76	-0.74	-0.83	0.55	-0.9	-0.68		-0.47	-0.62	-0.97	-0.93	-0.52	0.76	-0.94	-0.8	-0.78	-0.62	-0.94
Other Current Liab	0.61	0.7	0.54	0.47	0.51	0.41	0.46	0.65	0.67	0.47	0.7	-0.21	0.67	0.63	-0.47		0.6	0.52	0.49	0.68	-0.62	0.52	0.44	0.41	0.57	0.67
Common Stock Shares Outstanding	0.7	0.66	0.66	0.76	0.6	0.55	0.59	0.65	0.63	0.66	0.7	-0.29	0.71	0.59	-0.62	0.6		0.63	0.59	0.54	-0.61	0.61	0.45	0.54	0.73	0.67
Short Long Term Debt Total	0.95	0.69	0.98	0.96	1.0	0.97	0.99	0.72	0.66	0.74	0.75	-0.69	0.83	0.75	-0.97	0.52	0.63		0.99	0.41	-0.65	0.89	0.85	0.65	0.68	0.88
Property Plant And Equipment Net	0.89	0.59	0.94	0.95	1.0	0.95	0.99	0.63	0.56	0.69	0.66	-0.77	0.75	0.74	-0.93	0.49	0.59	0.99		0.3	-0.55	0.83	0.85	0.55	0.68	0.82
Current Deferred Revenue	0.64	0.94	0.51	0.38	0.37	0.34	0.31	0.91	0.95	0.39	0.9	0.09	0.79	0.48	-0.52	0.68	0.54	0.41	0.3		-0.94	0.54	0.12	0.85	0.38	0.73
Net Debt	-0.84	-0.99	-0.74	-0.62	-0.62	-0.61	-0.57	-0.99	-0.99	-0.56	-0.98	0.12	-0.92	-0.61	0.76	-0.62	-0.61	-0.65	-0.55	-0.94		-0.75	-0.36	-0.95	-0.52	-0.89
Non Current Assets Total	0.95	0.79	0.96	0.83	0.87	0.93	0.87	0.8	0.74	0.82	0.85	-0.3	0.93	0.62	-0.94	0.52	0.61	0.89	0.83	0.54	-0.75		0.83	0.72	0.59	0.95
Non Currrent Assets Other	0.78	0.42	0.86	0.79	0.85	0.92	0.88	0.42	0.36	0.7	0.5	-0.52	0.64	0.51	-0.8	0.44	0.45	0.85	0.85	0.12	-0.36	0.83		0.28	0.47	0.7
Other Assets	0.8	0.92	0.71	0.62	0.62	0.6	0.58	0.95	0.94	0.48	0.91	-0.17	0.87	0.51	-0.78	0.41	0.54	0.65	0.55	0.85	-0.95	0.72	0.28		0.46	0.84
Long Term Debt	0.66	0.55	0.65	0.71	0.67	0.55	0.65	0.6	0.52	0.64	0.6	-0.41	0.67	0.84	-0.62	0.57	0.73	0.68	0.68	0.38	-0.52	0.59	0.47	0.46		0.67
Cash And Short Term Investments	0.97	0.92	0.94	0.83	0.86	0.86	0.84	0.93	0.89	0.76	0.95	-0.32	0.99	0.72	-0.94	0.67	0.67	0.88	0.82	0.73	-0.89	0.95	0.7	0.84	0.67

Click cells to compare fundamentals

Moderna Account Relationship Matchups

Moderna fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.6B	7.3B	24.7B	25.9B	18.4B	19.3B
Total Current Liabilities	143.1M	4.4B	9.1B	4.9B	3.0B	2.4B
Total Stockholder Equity	1.2B	2.6B	14.1B	19.1B	13.9B	14.5B
Other Liab	139.1M	179.3M	691M	808M	929.2M	975.7M
Net Tangible Assets	1.2B	2.6B	14.1B	19.1B	22.0B	23.1B
Retained Earnings	(1.5B)	(2.2B)	10.0B	18.3B	13.6B	14.3B
Accounts Payable	7.1M	18M	302M	487M	520M	546M
Cash	235.9M	2.6B	6.8B	3.2B	2.9B	1.8B
Net Receivables	16.3M	1.4B	3.2B	1.4B	892M	848.5M
Other Current Assets	887.9M	252M	607M	1.4B	643M	462.8M
Total Liab	414.6M	4.8B	10.5B	6.7B	4.6B	3.1B
Total Current Assets	1.3B	6.3B	16.1B	13.4B	10.3B	5.6B
Common Stock	33K	34K	40K	(857M)	(771.3M)	(732.7M)
Other Current Liab	5.1M	4.3B	1.5B	2.2B	1.8B	1.2B
Common Stock Shares Outstanding	330.8M	381.3M	431M	416M	382M	346.5M
Short Long Term Debt Total	132.4M	207.3M	916M	1.2B	1.2B	1.3B
Property Plant And Equipment Net	287.9M	387M	1.4B	2.1B	2.7B	2.8B
Current Deferred Revenue	63.3M	3.9B	6.3B	2.0B	568M	539.6M
Net Debt	(103.5M)	(2.6B)	(6.8B)	(3.2B)	(1.7B)	(1.7B)
Non Current Assets Total	326.4M	1.0B	8.6B	12.4B	8.1B	4.3B
Non Currrent Assets Other	(121.5M)	13M	46M	946M	523M	549.2M
Other Assets	12.7M	742.0M	7.4B	1.9B	2.2B	1.6B
Cash And Short Term Investments	1.3B	4.6B	10.7B	9.9B	8.6B	5.3B
Short Term Investments	867.1M	2.0B	3.9B	6.7B	5.7B	3.0B
Liabilities And Stockholders Equity	1.6B	7.3B	24.7B	25.9B	18.4B	11.3B
Non Current Liabilities Total	271.5M	387M	1.4B	1.8B	1.6B	868.0M
Capital Surpluse	2.7B	4.8B	4.2B	1.2B	1.3B	2.4B
Capital Lease Obligations	132.4M	207.3M	916M	1.0B	1.2B	1.3B
Other Stockholder Equity	2.7B	4.8B	4.2B	1.2B	371M	352.5M
Long Term Investments	160.0M	638.8M	6.8B	8.3B	4.7B	2.9B
Accumulated Other Comprehensive Income	1.8M	3M	(24M)	(370M)	(123M)	(116.9M)
Non Current Liabilities Other	138K	386.6M	1.4B	135M	256M	299.3M
Short Term Debt	67.7M	30M	1.1B	244M	25M	23.8M
Property Plant Equipment	287.9M	387.1M	1.4B	2.1B	2.5B	2.6B
Net Invested Capital	1.2B	2.6B	14.1B	19.1B	13.9B	8.1B
Property Plant And Equipment Gross	287.9M	387.1M	1.7B	2.1B	3.1B	3.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:

How To Invest In Moderna

Details

Is Moderna Stock a good investment?

Details

What is Moderna's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.85)

Earnings Share

(5.81)

Revenue Per Share

13.275

Quarterly Revenue Growth

0.017

Return On Assets

(0.1)

The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Moderna Free Cash Flow Per Share vs Ev To Sales Analysis

Free Cash Flow Per Share vs Ev To Sales

Free Cash Flow Per Share vs Ev To Sales Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Ev To Sales

Moderna fundamental ratios Correlations

Moderna Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Moderna fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 1.0	Total Current Liabilities
Short Long Term Debt Total	+ 1.0	Net Tangible Assets
Property Plant And Equipment Net	+ 1.0	Net Tangible Assets
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities

Net Debt	- 0.99	Net Receivables
Net Debt	- 0.99	Cash
Net Debt	- 0.99	Total Current Liabilities
Net Debt	- 0.98	Total Liab
Common Stock	- 0.98	Total Stockholder Equity
Common Stock	- 0.98	Total Assets